New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
12:27 EDTHUM, GNW, RT, REGN, TWTR, DEST, NQOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday, with the Nasdaq leading and the Dow lagging, after a much better than expected reading on second quarter economic growth in the U.S. and ahead of a statement from the Federal Reserve following its latest policy meeting. With a solid earnings season and the economic data showing growth, investors are now on Fed watch, with the move in the averages potentially illustrating fear that the central bank may begin to get more hawkish. ECONOMIC EVENTS: In the U.S., the Commerce Department estimated that Gross Domestic Product grew at a seasonally adjusted annual rate of 4.0% in the second quarter, easily beating expectations for a growth rate of 3.0%. Payroll company ADP reported private payrolls climbed 218K in July, which was a bit below the 238K forecast. The Federal Reserve wraps up its two-day Federal Open Market Committee meeting today and the accompanying rate decision and statement is scheduled to be released at 2:00 pm ET. COMPANY NEWS: Shares of Twitter (TWTR) surged 20% higher after the social network operator's second quarter results beat analysts' consensus estimates and it raised its fiscal year 2014 revenue and adjusted EBITDA forecasts. Following last night's report, Bank of America Merrill Lynch upgraded Twitter to Buy from Neutral, while the stock was also upgraded to Outperform from Sector Perform at FBN Securities, to Neutral from Sell at UBS and to Market Perform from Underperform at Cowen. MAJOR MOVERS: Among the notable gainers was NQ Mobile (NQ), which jumped 15% to trade near $8 per share after the company reported it has received a non-binding proposal from Bison Capital to acquire all of NQ's outstanding American depositary shares for $9.80 each. Also higher was Regeneron (REGN), which rose 6% after the company announced that nine new Phase 3 Odyssey trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint. Among the noteworthy losers was Genworth Financial (GNW), which dropped 13% and was downgraded to Neutral from Outperform at Macquarie after its second quarter earnings report. Also lower following their earnings reports were Humana (HUM), which slid 5%, Ruby Tuesday (RT), which fell over 16%, and Destination Maternity (DEST), which dropped more than 19%. INDEXES: Near midday, the Dow was down 57.70, or 0.34%, to 16,854.41, the Nasdaq was up 9.01, or 0.2%, to 4,451.71, and the S&P 500 was down 3.87, or 0.2%, to 1,966.08.
News For TWTR;GNW;NQ;REGN;HUM;DEST;RT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 24, 2015
14:06 EDTREGNRegeneron trading halted, pending news
11:22 EDTTWTRTwitter volatility elevated into Q2 and outlook
Subscribe for More Information
08:45 EDTREGNRegeneron cholesterol treatment likely to be approved today, says Bernstein
Bernstein notes that today is the PDUFA day for Regeneron's (REGN) and Amgen's (AMGN) Praluent, which would be the first antibody approved for cholesterol treatment in the U.S. The firm expects the drug to be approved today. After surveying doctors on the drug, Bernstein finds that their attitudes towards it are "remarkably positive." The firm keeps an Outperform rating on Regeneron and a Market Perform rating on Amgen.
07:21 EDTREGNRegeneron, Sanofi say CHMP recommends Euro approval of Praluent treatment
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicine Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for the marketing authorization of Praluent, recommending its approval for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9. The European Commission is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September. The CHMP opinion was based on the benefit-risk profile of Praluent, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show consistent, positive results in reducing LDL-C. The U.S. Food and Drug Administration has set a target action date of July 24 for the Biologics License Application of Praluent. The safety and efficacy of Praluent have not been fully evaluated by any other regulatory authority.
07:18 EDTREGNRegeneron and Sanofi's Praluent recommended for approval in Europe
Regeneron (REGN) and Sanofi (SNY) announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent, recommending its approval for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9. The European Commission is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September.
07:16 EDTREGNFDA PDUFA Date for Regeneron and Sanofi BLA for Praluent is July 24, 2015
Subscribe for More Information
05:53 EDTTWTRStocks with implied volatility above IV index mean; AMZN TWTR
Subscribe for More Information
July 23, 2015
20:01 EDTTWTRTwitter announces event targeting
Twitter announced, on its blog, that the company is instituting event-based advertisement targeting. The company stated that event targeting utilizes three tools, an event calendar, event insights, and event activation. The company stated, "With event targeting, you can activate around live moments, quickly and easily. We’ll help you discover and plan for these moments, learn more about the participating audiences through valuable insights, and with one click, create a campaign that delivers the right message to just the right users as the event unfolds." Event targeting is now available to all Twitter advertisers globally. Reference Link
16:25 EDTRTRuby Tuesday sees FY16 adjusted EPS 12c-17c, consensus 7c
Sees FY16 same-restaurant sales to be in the range of flat to up 2%. Q1-to-date, same-restaurant sales are in-line with this range.
16:25 EDTRTRuby Tuesday reports Q4 adjusted EPS 12c, consensus 10c
Subscribe for More Information
07:50 EDTTWTRBrean Capital cuts Twitter target to $47 on near-term risks
Subscribe for More Information
July 22, 2015
10:01 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:39 EDTREGNRegeneron initiated with a Market Perform at Northland
Northland analyst James Kuo started shares of Regeneron Pharmaceuticals with a Market Perform rating and $500 price target. Pointing out that shares are up 34% year-to-date and 80% year-over-year, Kuo prefers to watch the upcoming launch of Praluent from the sidelines.
07:41 EDTTWTRTwitter blocked by Turkey following recent terror attack, AP reports
Subscribe for More Information
06:12 EDTTWTRHerbalife requests user information from Twitter, Reuters reports
Herbalife (HLF) has filed a petition seeking information from Twitter (TWTR) to find an anonymous user who posted defamatory tweets against Herbalife, Reuters reports. Herbalife wants Twitter to provide IP addresses as well as account details of the user so that the company can pursue legal action, the report says. Reference Link
05:21 EDTGNWGenworth enters into talks with AXA to sell lifestyle protection business
Genworth Financial (GNW) announces it has entered into exclusive negotiations with AXA S.A. (AXAHY) after receiving an irrevocable offer to purchase its lifestyle protection insurance business. The company expects to accept the offer and execute an associated purchase agreement upon completion of the French works council consultation process. The sale price is expected to be approximately $510M and the company will record an after-tax loss of approximately $310M in Q2 related to the expected sale and pension settlement costs. Net proceeds from the transaction, net of pension settlement costs and transaction related expenses, are estimated to be approximately $400M. Genworth plans to use these proceeds to advance compliance with the Private Mortgage Insurer Eligibility Requirements and to reduce debt levels. The sale is expected to close by the end of 2015 and is subject to other customary conditions, including requisite regulatory approvals.
July 21, 2015
16:21 EDTRTRuby Tuesday appoints David Skena as Chief Marketing Officer
Subscribe for More Information
12:47 EDTREGNPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
July 20, 2015
10:05 EDTHUMHumana renews, lengthens SilverSneakers pact with Healthways
Subscribe for More Information
06:06 EDTTWTRStocks with implied volatility above IV index mean; XOMA TWTR
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use